SELECT PUBLICATIONS

Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.

Allred D et al. ER status and response to tamoxifen in ductal carcinoma in situ (DCIS): Findings from NSABP protocol B-24. Presentation. San Antonio Breast Cancer Symposium 2002;30. No abstract available

Blum JL et al. A Phase II trial of combination therapy with capecitabine and weekly paclitaxel for metastatic breast cancer (MBC): Preliminary results in taxane-naïve patients. Poster. San Antonio Breast Cancer Symposium 2004;Abstract 5053.

Blum JL et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer. Proc ASCO 2003;Abstract 64.

Burstein HJ et al. Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. Proc ASCO 2005;Abstract 529.

Chlebowski RT et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS). Proc ASCO 2005;Abstract 10.

Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer 2005;6(Suppl 1):15-22. Abstract

Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. Proc ASCO 2005;Abstract 658.

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13. Abstract

Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. BMJ 2005;331(7524):1035-6. No abstract available

Di Costanzo F et al. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: Dose-finding trial of GOIRC and GOL. Ann Oncol 2006;17(1):79-84. Abstract

Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;31(4):274-82. Abstract

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract

El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005;14(5):368-74. Abstract

Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract

Fisher B et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169):1993-2000. Abstract

Frisby KA et al. Clinical trial accrual patterns and barriers among newly diagnosed adult patients at a community cancer center: A prospective study. Proc ASCO 2005;Abstract 6017.

Fumoleau P et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40(4):536-42. Abstract

Fyles AW et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351(10):963-70. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Gradishar WJ. Clinical value of fulvestrant in breast cancer. Clin Breast Cancer 2005;6(Suppl 1):4. No abstract available

Gradishar WJ, Sahmoud T. Current and future perspectives on fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):23-9. Abstract

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract

Guarino MJ et al. Barriers exist to patient participation in clinical trials. Proc ASCO 2005;Abstract 6015.

Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract

Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. No abstract available

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 2005;93(2-5):237-47. Abstract

Hughes KS et al; Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351(10):971-7. Abstract

Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl 1):9-14. Abstract

Jones SE et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51. Abstract

Julian TB et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Presentation. San Antonio Breast Cancer Symposium 2004;Abstract 14.

Kara IO et al. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2005;[Epub ahead of print]. Abstract

Kudachadkar R, O’Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145-63. Abstract

Lee KS et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC). San Antonio Breast Cancer Symposium 2005;Abstract 5052.

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Marty M et al. Anthracyclines vs taxanes plus trastuzumab in HER2-positive metastatic breast cancer (MBC): A cross trial comparison of pivotal studies. Proc ASCO 2005;Abstract 743.

Mavroudis D et al. A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report. San Antonio Breast Cancer Symposium 2005;Abstract 6089.

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long term disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.

O’Shaughnessy J et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556. Perez EA et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Proc ASCO 2004;Abstract 567.

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract

Pippen J et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: A prospective combined survival analysis of two multicenter trials. Poster. San Antonio Breast Cancer Symposium 2003;Abstract 426.

Reichardt P et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14(8):1227-33. Abstract

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Runnebaum IB, Bruning A. Glucocorticoids inhibit cell death in ovarian cancer and upregulate caspase inhibitor cIAP2. Clin Cancer Res 2005;11(17):6325-32. Abstract

Schott AF et al. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol 2005;[Epub ahead of print]. Abstract

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1- hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract

Tabernero J et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15(9):1358-65. Abstract

Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract

Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract

Umutyan A et al. Overcoming barriers to accrual: An assessment of 1,187 cancer patients’ (Pts) and caregivers’ awareness of and willingness to participate in cancer clinical trials (CCTs). Proc ASCO 2005;Abstract 6016.

Vogel VG et al. National surgical adjuvant breast and bowel project update: Prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 2003;9(1 Pt 2):495-501. Abstract

Von Minckwitz G et al. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy — First results of the phase III GEPARTRIO-Study by the German Breast Group. San Antonio Breast Cancer Symposium 2005;Abstract 38.

Wagstaff AJ et al. Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63(2):217-36. Abstract

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005;23(3):619- 29. Abstract